icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
Efficacy by Race or Geographic Region in HCV Genotype 1-Infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin
 
 
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
 
John Vierling1, Massimo Puoti 2, David Bernstein3, Naoky Tsai4, Ola Weiland5, Manuel Romero-Gómez6, Florin Alexandru Caruntu7, Jean-Francois DuFour8, Filipe Calinas9, Lois Larsen10, Fernando Tatsch10,
Pietro Andreone11
1Baylor College of Medicine and Advanced Liver Therapies, Houston, Texas, United States; 2AO Ospedale Niguarda Ca Granda, Milan, Italy; 3North Shore University Hospital, Manhasset, New York, United States; 4Queen's Medical Center, University of Hawaii, Honolulu, Hawaii, United States;
5Karolinska University Hospital Huddinge, Karolinska Insti tutet, Stockholm, Sweden; 6Hospital Universitario Nuestra Señora de Valme, Seville, Spain; 7Nati onal Insti tute for Infecti ous Diseases "Matei Bals," Bucharest, Romania; 8University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 9Centro Hospitalar Lisboa Central, EPE - Hosp. St. Antonio dos Capuchos, Lisbon, Portugal; 10AbbVie Inc., North Chicago, Illinois, United States; 11Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif